Eiger BioPharmaceuticals Inc
NASDAQ:EIGR 4:00:00 PM EDT
| Market Cap (Intraday) | 15.31M |
| Current PE | N/A |
| Forward PE | N/A |
| 2yr Forward PE | N/A |
| 10-Day MA | $0.34 |
| 50-Day MA | $0.31 |
| 200-Day MA | $0.84 |
Eiger BioPharmaceuticals Inc Stock, NASDAQ:EIGR
2155 Park Boulevard, 2155 Park Boulevard, Palo Alto, California 94306-1543
United States of America
Phone: +1.650.272.6138
Number of Employees: 56
Description
Eiger BioPharmaceuticals, Inc. engages in the development and commercialization of foundational therapies for Hepatitis Delta Virus. It is also developing avexitide as a treatment for Post-Bariatric Hypoglycemia. The company was founded by David A. Cory and Glenn S. Jeffrey on November 6, 2008 and is headquartered in Palo Alto, CA.